Sellas Life Sciences Group

SLS · NASDAQ

$11.98+$1.49 (+14.20%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $10.49

SLS analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $33.15 (+176.7% upside)

Low: $30.30
Now: $11.98
High: $36.75

Upgrades and downgrades

The latest rating actions, newest first

SLS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Mar 12, 2026	Maintains	Buy	$7.00 → $10.00	27%

The case for and against

Updated Nov 28, 2024

Bull case

SELLAS Life Sciences Group Inc is well-positioned for future growth due to its advanced product candidates, particularly galinpepimut-S, which is currently in Phase 3 trials, and GFH009, a CDK9 inhibitor that complements its immunotherapy pipeline. The company's strategic focus on addressing significant unmet needs in cancer treatment enhances its market potential, particularly in light of the increasing prevalence of resistant relapsed patients. Furthermore, the positive advancements in clinical positioning and community relationships bolster SELLAS's operational capabilities and future commercial efficiencies, contributing to a favorable long-term outlook.

Bear case

SELLAS Life Sciences Group Inc is facing significant financial challenges that contribute to a negative outlook on its stock. The inability to secure additional resources and address high operational costs could hinder the company's progress in advancing its product candidates, particularly galinpepimut-S and GFH009. Furthermore, external factors such as geographical risks and fluctuating market conditions, including weaker metals prices, may complicate capital raising efforts and inhibit potential acquisition opportunities.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.